Patricia Marr1, Sharon Walmsley. 1. University Health Network, Immunodeficiency Clinic, 13 North, Room 1314, 200 Elizabeth Street, Toronto, ON M5G2C4, Canada. patricia.marr@uhn.on.ca
Abstract
BACKGROUND: The development of new protease inhibitors, new non-nucleoside reverse transcriptase inhibitors and novel therapeutic drug classes has dramatically changed the approach to managing HIV-1 patients with multidrug resistant virus. This has led many clinicians to reevaluate the clinical utility of enfuvirtide. OBJECTIVES: To summarize recent literature on enfuvirtide and to reassess enfuvirtide's role in the management of HIV-1 infection. METHODS: MEDLINE (1990 to February Week 2 2008) and EMBASE (1990 to 2008 week 8) databases were searched using the following terms: 'enfuvirtide', 'Fuzeon', 'T20', 'HIV fusion inhibitors', and 'HIV entry inhibitor'; limits: English language. Reference lists of articles deemed relevant were hand searched for additional publications. Significant abstracts from recent international HIV conferences were also identified. CONCLUSION: Enfuvirtide can optimize the response to new combinations of HIV-1 drug regimens in multiresistant patients. Its inclusion as an active agent is effective but use is impacted by its high cost, inconvenient route of administration and cosmetic side-effect profile.
BACKGROUND: The development of new protease inhibitors, new non-nucleoside reverse transcriptase inhibitors and novel therapeutic drug classes has dramatically changed the approach to managing HIV-1patients with multidrug resistant virus. This has led many clinicians to reevaluate the clinical utility of enfuvirtide. OBJECTIVES: To summarize recent literature on enfuvirtide and to reassess enfuvirtide's role in the management of HIV-1 infection. METHODS: MEDLINE (1990 to February Week 2 2008) and EMBASE (1990 to 2008 week 8) databases were searched using the following terms: 'enfuvirtide', 'Fuzeon', 'T20', 'HIV fusion inhibitors', and 'HIV entry inhibitor'; limits: English language. Reference lists of articles deemed relevant were hand searched for additional publications. Significant abstracts from recent international HIV conferences were also identified. CONCLUSION: Enfuvirtide can optimize the response to new combinations of HIV-1 drug regimens in multiresistant patients. Its inclusion as an active agent is effective but use is impacted by its high cost, inconvenient route of administration and cosmetic side-effect profile.
Authors: George J Hanna; Jacob Lalezari; James A Hellinger; David A Wohl; Richard Nettles; Anna Persson; Mark Krystal; Pinfang Lin; Richard Colonno; Dennis M Grasela Journal: Antimicrob Agents Chemother Date: 2010-11-15 Impact factor: 5.191
Authors: Matteo Porotto; Barry Rockx; Christine C Yokoyama; Aparna Talekar; Ilaria Devito; Laura M Palermo; Jie Liu; Riccardo Cortese; Min Lu; Heinz Feldmann; Antonello Pessi; Anne Moscona Journal: PLoS Pathog Date: 2010-10-28 Impact factor: 6.823
Authors: Xingrong Liu; Ying C Ou; Jun Zhang; Ago Ahene; Douglas Clark; Su-Chun Hsieh; Matthew Cooper; Changhua Ji Journal: Pharm Res Date: 2013-09-25 Impact factor: 4.200